IP Library Granted Patent US 6,867,226
Granted Patent B2
US 6,867,226 · App. 10/219,496 · Granted Mar 15, 2005

Serotonin 5-HT3 receptor partial activator

Assignee: Meiji Seika Kaisha, Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,867,226
App. No.
10/219,496
Granted
Mar 15, 2005
Kind
B2
Abstract

This invention provides a serotonin 5-HT 3 receptor partial activator which has a serotonin 5-HT 3 receptor activating action, in addition to its serotonin 5-HT 3 receptor antagonism, and does not cause constipation as a side effect. Particularly, based on the finding that newly synthesized benzoxazole derivatives typified by the compounds of the following formula (2) have strong serotonin 5-HT 3 receptor antagonism and serotonin 5-HT 3 receptor activating action, this invention provides these benzoxazole derivatives as serotonin 5-HT 3 receptor partial activators. In the above formula, R 1 to R 4 may be the same or different from one another and each represents a hydrogen atom, a halogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted lower alkenyl group or a substituted or unsubstituted amino group, or two groups of R 1 and R 2 may be linked together to form a ring structure, namely benzene ring; R 5 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group or a substituted or unsubstituted lower alkenyl group; and m is an integer of 1 to 4.

Claims (3)

1. A method for treating irritable colon syndrome, which comprises administering to a subject in need of treatment a pharmaceutically effective amount of a pharmaceutical composition which comprises, as its active ingredient, the compound represented by formula (2):

wherein R 1 to R 4 are the same or different from one another and each represents a hydrogen atom, a halogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted lower alkenyl group or a substituted or unsubstituted amino group, or two groups of R 1 and R 2 are linked together to form a benzene ring and R 3 and R 4 are hydrogen atoms, with the proviso that compounds in which all of R 1 to R 4 are hydrogen atoms are excluded; R 5 represents a hydrogen atom; and m is an integer of 3, in which said lower alkyl group means a straight or branched C 1 -C 4 alkyl group, said lower alkenyl group means a straight or branched C 2 -C 4 alkenyl group, the substituent for said lower alkyl or lower alkenyl group is selected from the group consisting of a halogen atom, a hydroxyl group, a carbamoyl group, an amino group and a cyano group, the substituent for said amino group is selected from the group consisting of a straight or branched C 1 -C 4 alkyl group, a straight or branched C 1 -C 4 alkycarbonyl group, a straight or branched C 2 -C 4 alkenyl group and a benzylidene group which may have a phenyl group, and said halogen atom is selected from the group consisting of fluorine, chlorine, bromine and iodine atoms,

and which further comprise a pharmaceutically acceptable carrier.

Assignments (3)
CHANGE OF NAME Recorded Apr 28, 2010
From: ORDER-MADE SOUYAKU CO., LTD.
To: LOTUS PHARMACEUTICAL CO., LTD.
Reel/Frame 024329/0653 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2009
From: R & R INC; SHUDO, KOICHI
To: ORDER-MADE SOUYAKU CO., LTD.
Reel/Frame 022846/0569 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2007
From: MEIJI SEIKA KAISHA LTD.
To: R&R INC.
Reel/Frame 019407/0155 →
Priority Claims (2)
JP P. 8-115008 · May 9, 1996 · national
JP P. 9-93821 · Apr 11, 1997 · national
Continuity (2)
Division 0979680500 · Mar 2, 2001
Related Publication 20030013730A1 · Jan 16, 2003